Healthcare and Pharmaceuticals
Total 2 reports found
Cannabinoid Intoxication Treatment Drug Market, Global Outlook and Forecast 2022-2028
August 2024*COVID-19
Marijuana intoxication is the euphoria, relaxation, and sometimes undesirable side effects that can occur when people use marijuana. The ability to perform complex tasks may be adversely affected. Many users report excessive appetite after marijuana use.Toxicity associated with synthetic cannabinoids can be more severe, requiring more aggressive treatment. Agitation or acute psychosis should be treated with benzodiazepines or, if necessary, antipsychotic agents, such as haloperidol or olanzapine. This report contains market size and forecasts of Cannabinoid Intoxication Treatment Drug in global, including the following market information: Global Cannabinoid Intoxication Treatment Drug Market Revenue, 2017-2022, 2023-2028, ($ millions) Global Cannabinoid Intoxication Treatment Drug Market Sales, 2017-2022, 2023-2028, (K Units) Global top five Cannabinoid Intoxication Treatment Drug companies in 2021 (%) The global Cannabinoid Intoxication Treatment Drug market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028. The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028. Benzodiazepines Segment to Reach $ Million by 2028, with a % CAGR in next six years. The global key manufacturers of Cannabinoid Intoxication Treatment Drug include Oregon Poison Center, Indiana Poison Center, MedVet, Mill Creek Animal Hospital and VCA, etc. In 2021, the global top five players have a share approximately % in terms of revenue. MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Cannabinoid Intoxication Treatment Drug manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks. Total Market by Segment: Global Cannabinoid Intoxication Treatment Drug Market, By Type, 2017-2022, 2023-2028 ($ Millions) & (K Units) Global Cannabinoid Intoxication Treatment Drug Market Segment Percentages, By Type, 2021 (%) Benzodiazepines Haloperidol Olanzapine Others Global Cannabinoid Intoxication Treatment Drug Market, By Application, 2017-2022, 2023-2028 ($ Millions) & (K Units) Global Cannabinoid Intoxication Treatment Drug Market Segment Percentages, By Application, 2021 (%) Hospital Pharmacies Retail Pharmacies Online Pharmacies Global Cannabinoid Intoxication Treatment Drug Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units) Global Cannabinoid Intoxication Treatment Drug Market Segment Percentages, By Region and Country, 2021 (%) North America US Canada Mexico Europe Germany France U.K. Italy Russia Nordic Countries Benelux Rest of Europe Asia China Japan South Korea Southeast Asia India Rest of Asia South America Brazil Argentina Rest of South America Middle East & Africa Turkey Israel Saudi Arabia UAE Rest of Middle East & Africa Competitor Analysis The report also provides analysis of leading market participants including: Key companies Cannabinoid Intoxication Treatment Drug revenues in global market, 2017-2022 (Estimated), ($ millions) Key companies Cannabinoid Intoxication Treatment Drug revenues share in global market, 2021 (%) Key companies Cannabinoid Intoxication Treatment Drug sales in global market, 2017-2022 (Estimated), (K Units) Key companies Cannabinoid Intoxication Treatment Drug sales share in global market, 2021 (%) Further, the report presents profiles of competitors in the market, key players include: Oregon Poison Center Indiana Poison Center MedVet Mill Creek Animal Hospital VCA
Oculopharyngeal Muscular Dystrophy (OPMD) Market, Global Outlook and Forecast 2022-2028
August 2024*COVID-19
Oculopharyngeal muscular dystrophy?(OPMD) is a rare genetic muscle disorder with onset during adulthood most often between 40 and 60 years of age. OPMD is characterized by slowly progressive muscle disease (myopathy) affecting the muscles of the upper eyelids and the throat. This report contains market size and forecasts of Oculopharyngeal Muscular Dystrophy (OPMD) in global, including the following market information: Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Revenue, 2017-2022, 2023-2028, ($ millions) Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Sales, 2017-2022, 2023-2028, (K Units) Global top five Oculopharyngeal Muscular Dystrophy (OPMD) companies in 2021 (%) The global Oculopharyngeal Muscular Dystrophy (OPMD) market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028. The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028. Tablets Segment to Reach $ Million by 2028, with a % CAGR in next six years. The global key manufacturers of Oculopharyngeal Muscular Dystrophy (OPMD) include Benitec Biopharma Inc., Bioblast Pharma, BioMarin, PTC Therapeutics, NS Pharma, Nobelpharma Co., Ltd, Santhera Pharmaceuticals, Pfizer Inc. and Marathon Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue. MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Oculopharyngeal Muscular Dystrophy (OPMD) manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks. Total Market by Segment: Global Oculopharyngeal Muscular Dystrophy (OPMD) Market, By Type, 2017-2022, 2023-2028 ($ Millions) & (K Units) Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Segment Percentages, By Type, 2021 (%) Tablets Capsules Injectable Other Global Oculopharyngeal Muscular Dystrophy (OPMD) Market, By Application, 2017-2022, 2023-2028 ($ Millions) & (K Units) Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Segment Percentages, By Application, 2021 (%) Hospital Pharmacies Retail Pharmacies Online Pharmacies Global Oculopharyngeal Muscular Dystrophy (OPMD) Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units) Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Segment Percentages, By Region and Country, 2021 (%) North America US Canada Mexico Europe Germany France U.K. Italy Russia Nordic Countries Benelux Rest of Europe Asia China Japan South Korea Southeast Asia India Rest of Asia South America Brazil Argentina Rest of South America Middle East & Africa Turkey Israel Saudi Arabia UAE Rest of Middle East & Africa Competitor Analysis The report also provides analysis of leading market participants including: Key companies Oculopharyngeal Muscular Dystrophy (OPMD) revenues in global market, 2017-2022 (Estimated), ($ millions) Key companies Oculopharyngeal Muscular Dystrophy (OPMD) revenues share in global market, 2021 (%) Key companies Oculopharyngeal Muscular Dystrophy (OPMD) sales in global market, 2017-2022 (Estimated), (K Units) Key companies Oculopharyngeal Muscular Dystrophy (OPMD) sales share in global market, 2021 (%) Further, the report presents profiles of competitors in the market, key players include: Benitec Biopharma Inc. Bioblast Pharma BioMarin PTC Therapeutics NS Pharma Nobelpharma Co., Ltd Santhera Pharmaceuticals Pfizer Inc. Marathon Pharmaceuticals Fibrogen Bristol-Myers Squibb Sarepta Therapeutics GSK